Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered
as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma
(R/R MM).